For the hundreds of millions living with diabetes worldwide, cardiac complications remain the leading cause of death — yet the precise molecular machinery connecting metabolic dysregulation to heart muscle deterioration has remained poorly mapped. This review repositions cellular senescence not as a bystander but as the mechanistic hub linking diabetic metabolic stress to irreversible cardiac remodeling, potentially reframing how cardiologists and endocrinologists approach prevention and treatment.
Diabetic cardiomyopathy represents a structurally and functionally distinct cardiac syndrome, arising independently of hypertension or coronary artery disease. The review synthesizes evidence showing that sustained cell-cycle arrest in cardiomyocytes and cardiac progenitor cells, combined with mitochondrial quality control failures, drives the condition at its core. Central regulators implicated include Sirtuin 3 (SIRT3) and ATP synthase O subunit (ATP5O), whose dysfunction impairs mitochondrial integrity under chronic hyperglycemic stress. Aberrant activation of p53 signaling and the FOXO1–Angiopoietin-like 4 (ANGPTL4) axis, alongside miRNA-dependent pathways, propagates senescence across cardiac cell populations. Compounding this, the senescence-associated secretory phenotype (SASP) sustains a proinflammatory microenvironment that polarizes macrophages and accelerates myocardial fibrosis. Notably, the authors distinguish type 1 from type 2 diabetes, suggesting different senescence burden profiles and mitochondrial impairment signatures between them — a nuance rarely addressed in the literature.
This synthesis arrives at a timely moment. Senolytics — drugs that selectively eliminate senescent cells — have attracted growing preclinical interest, and SASP-suppressing agents (senostatics) are entering early clinical evaluation. The SIRT3 axis, in particular, intersects with established longevity biology, suggesting metabolic and anti-aging interventions may share mechanistic territory. However, this is a narrative review, not a meta-analysis or clinical trial, meaning its conclusions are mechanistically plausible but not yet causally validated in humans. The distinction drawn between diabetes subtypes is intellectually significant but requires dedicated longitudinal cohort data. Overall, this represents an important conceptual synthesis that could catalyze therapeutic target prioritization, though translation into clinical senolytics for diabetic cardiomyopathy remains at an early stage.
